ABSTRACT
A multicenter, prospective clinical trial was performed to study efficacy and tolerance of a compound drug PRO 160/120 in the elderly men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). A total of 257 patients were randomized into two groups. Group 1 of 129 patients received PRO 160/120; group 2 of 128 patients received placebo. In 2-week induction blind phase of placebo the patients received for 24 weeks 1 capsule of the drug or placebo twice a day in conditions of double blind study. The double blind phase was followed by an open control period for 24 weeks when all the patients received PRO 160/120. Treatment efficacy evaluation was based on I-PSS, quality of life index, urodynamic and ultrasonography evidence. PRO 160/120 was superior to placebo by attenuating LUTS assessed by I-PSS, improved obstructive and irritative symptoms, was effective in patients with moderate and severe symptoms. Tolerance of the plant extract was good.
Subject(s)
Plant Extracts/therapeutic use , Prostatic Hyperplasia/drug therapy , Urinary Tract/physiopathology , Urination Disorders/drug therapy , Aged , Double-Blind Method , Humans , Male , Middle Aged , Placebos , Prostatic Hyperplasia/complications , Prostatic Hyperplasia/diagnostic imaging , Quality of Life , Serenoa/chemistry , Severity of Illness Index , Treatment Outcome , Ultrasonography , Urination Disorders/etiology , Urodynamics/drug effects , Urtica dioica/chemistryABSTRACT
Spontaneous renal rupture is an infrequent event and is usually caused by a predisposing factor. Up to 178 cases have been published. We present a case of a large spontaneous perirenal hematoma caused by a perihilar renal cell carcinoma of a 1-cm diameter. Reviewing the literature, a classification of the condition is given according to the underlying pathology and mechanism of rupture. The need for explorative surgery in cases which cannot be clarified by noninvasive diagnostic tools is discussed.
